Generally, there appears to be a gradient of increasing tau binding: from absent to minimal tau binding in cognitively normal PD, to low tau binding in PD patients with cognitive impairment, to intermediate tau binding in DLB and very high tau binding in AD [102, 104]. The gene discussed is MAPT; the disease is Cognitive impairment.